Circle Pharma

South San Francisco, CA · Founded 2012 · Privately Held (backing)

Developer of a new generation of macrocycle therapies designed for cell-permeable delivery and can be delivered by multiple routes, including oral administration. Circle Pharma is based in South San Francisco, CA and was founded in 2012. It was valued at $269 million at its later-stage round in Jan 2025, the last priced event on record. It has raised $212 million across 4 recorded rounds; the latest was a $92.4 million later-stage round in Jun 2024.

PMV mark · valuation
$269.0M
Oct 2026
Priced at
its later-stage round
Jan 2025
Total raised
$212.1M
Last round
Later Stage VC
Jun 2024

Who backs Circle Pharma?

23 investors
InvestorType
Hemisphere VenturesVenture capital
CSC UpShot VenturesVenture capital
Mission BioCapitalVenture capital
Pfizer VenturesOther
Euclidean CapitalFamily office
Lifeforce CapitalVenture capital
Jude GomilaAngel
WI Harper GroupVenture capital
Eli Lilly and Company FoundationOther
Hartford Healthcare EndowmentOther
+ 13 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Circle Pharma investors

23 investors are on record for Circle Pharma, including Hemisphere Ventures, CSC UpShot Ventures, Mission BioCapital and Pfizer Ventures. By type, the record holds 5 venture capital firms and 1 family office. The later-stage round in Jun 2024 drew 14 investors.

Free account
More of Circle Pharma with a free account
  • ·The complete investor list: 23 names
  • ·Watch Circle Pharma: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 23 firms already write checks for companies like Circle Pharma. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View